News

Rio Tinto had announced on August 18, 2009, the receipt of a binding offer from Amcor for these businesses for a total consideration of $2.02b. The completion of

Rudolf Hanko, CEO of Siegfried, said: “Siegfried is one of the rare suppliers of the pharmaceutical industry that is capable of providing both the chemical synthesis of active

As part of the agreement, KMOT is expected to purchase prototype devices and rely on GT for establishing the technical approach and regulatory strategy for potential entry of

Reportedly, Ecoheart chewable tablets is the first animal product for which the company has received a marketing authorisation in Latin America. Further marketing authorisations in the key markets

Belinostat is also under investigation in a randomized phase 2 trial, as a combination therapy with carboplatin and paclitaxel, for cancer of unknown primary (CUP). Additionally, the NCI

As per the terms of the co-marketing alliance the companies will jointly promote the use of a new synthetic-ligand affinity adsorbent, marketed under the trade-name AlbuPure, as a

Under the collaboration and license agreement, Abbott will lead the development and commercialization of monoclonal antibodies targeting the cMet receptor. Pierre Fabre will receive an initial $25m upfront

Under the terms of the agreement, Therapure will be responsible for the manufacture of two major plasma proteins and LFB will remain responsible for global regulatory approvals and

Lee International will advise and assist TNS in the research and development of products most suitable for this market. The market includes Mainland China, Cambodia, Vietnam, Hong Kong,